ERBB2 and breast carcinoma: The differential impact of the combination therapy on stemness marker expression in SKBR3-R and HCC1954-R cells suggests that the level of Hedgehog pathway activation and the underlying molecular mechanisms of resistance may vary between different HER2-positive breast cancer cell lines.